Acute Radiation Syndrome (ARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Acute Radiation Syndrome (ARS) Market Outlook Thelansis’s “Acute Radiation Syndrome (ARS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Radiation Syndrome (ARS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Acute Radiation Syndrome (ARS) Overview Acute radiation syndrome (ARS) is a set of conditions that occur in humans following brief exposure to ionizing radiation at doses exceeding 0.7–1.0 Gy. The stages of ARS are as follows: Prodromal Phase: Begins within hours of exposure and can last up to 2 days. Latent Phase: A transitional period during which the patient shows no symptoms, las...